Barinthus Biotherapeutics (BRNS) FCF Margin (2020 - 2024)

Barinthus Biotherapeutics' (BRNS) quarterly FCF Margin came in at 122.33% in Q3 2024, up 97.27% on a QoQ basis from 4477.84% in Q2 2023.

Barinthus Biotherapeutics (BRNS) FCF Margin (2020 - 2024) Analysis & Trends

Barinthus Biotherapeutics (BRNS) has 5 years of FCF Margin data on file, last reported at 122.33% in Q3 2024.

Quarterly FCF Margin changed N/A year-over-year to 122.33% in Q3 2024, while the trailing twelve-month figure through Dec 2025 was 320.77% (down 12148.0% YoY) and the FY2024 annual result came in at 199.29%, up 616131.0% from the prior year.
FCF Margin grew to 122.33% in Q3 2024, from 4477.84% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 839600.0% in Q4 2021 to a low of 40691.43% in Q2 2021.
A 5-year average of 51500.24% and a median of 194.91% in 2020 frame the typical range for FCF Margin.
Annual changes were most pronounced in 2021 — FCF Margin surged 84103814 bps — and 2022, when it tumbled 83969834 bps.
Tracing BRNS's FCF Margin over 5 years: stood at 1438.14% in 2020, then jumped by 58481 bps to 839600.0% in 2021, then tumbled by 100 bps to 98.34% in 2022, then slumped by 4453 bps to 4477.84% in 2023, then soared by 97 bps to 122.33% in 2024.
The last three FCF Margin figures came in at 122.33% (Q3 2024), 4477.84% (Q2 2023), and 1213.89% (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.29 Bn	78.30 Bn	3.93 Bn	13.35%
3	Argenx Se	65.17 Bn	59.98 Bn	1.37 Bn	-
4	Moderna	61.38 Bn	56.24 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.18 Bn	37.09 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.99 Bn	27.68 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.45 Bn	10.05 Bn	668.28 Mn	41.07%
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	Barinthus Biotherapeutics	25.73 Mn	25.73 Mn	-	-

Download Data